Interindividual Variability in the Pharmacodynamic and Pharmacokinetic Characteristics of Recombinant Human Insulin and Insulin Aspart

Binder, 1984, Insulin pharmacokinetics, Diabetes Care, 7, 188, 10.2337/diacare.7.2.188 Heinemann, 2002, Variability of insulin absorption and insulin action, Diabetes Technol Ther, 4, 673, 10.1089/152091502320798312 Gin, 2005, Reproducibility and variability in the action of injected insulin, Diabetes Metab, 31, 7, 10.1016/S1262-3636(07)70160-X Mudaliar, 1999, Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects, Diabetes Care, 22, 1501, 10.2337/diacare.22.9.1501 Donner, 2019 Brange, 1990, Monomeric insulins and their experimental and clinical implications, Diabetes Care, 13, 923, 10.2337/diacare.13.9.923 Heinemann, 1998, Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart, Diabetes Care, 21, 1910, 10.2337/diacare.21.11.1910 Hompesch, 2008, Intra-individual variability of the metabolic effect of a novel rapid-acting insulin (VIAject) in comparison to regular human insulin, J Diabetes Sci Technol, 2, 568, 10.1177/193229680800200406 Woerle, 2007, Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels, Diabetes Res Clin Pract, 77, 280, 10.1016/j.diabres.2006.11.011 Home, 2012, The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences, Diabetes Obes Metab, 14, 780, 10.1111/j.1463-1326.2012.01580.x Nicolucci, 2020, Rapid-acting insulin analogues versus regular human insulin: a meta-analysis of effects on glycemic control in patients with diabetes, Diabetes Ther, 11, 573, 10.1007/s13300-019-00732-w Wojciechowski, 2015, Clinical efficacy and safety of insulin aspart compared with regular human insulin in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis, Pol Arch Med Wewn, 125, 141 Ma, 2012, A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study, Diabetes Technol Ther, 14, 589, 10.1089/dia.2011.0299 Østerberg, 2003, Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin, J Pharmacokinet Pharmacodyn, 30, 221, 10.1023/A:1025594110558 Nosek, 2013, Insulin aspart has a shorter duration of action than human insulin over a wide dose-range, Diabetes Obes Metab, 15, 77, 10.1111/j.1463-1326.2012.01677.x Rodbard, 2020, Biosynthetic human insulin and insulin analogs, Am J Ther, 27, e42, 10.1097/MJT.0000000000001089 Russell-Jones, 2017, Fast-acting insulin aspart improves glycemic control in basal-bolus treatment for type 1 diabetes: results of a 26-week multicenter, active-controlled, treat-to-target, randomized, parallel-group trial (onset 1), Diabetes Care, 40, 943, 10.2337/dc16-1771 Tinworth, 2011, Evaluation of commercially available assays for the measurement of equine insulin, Domest Anim Endocrinol, 41, 81, 10.1016/j.domaniend.2011.05.001 Shen, 2019, Insulin: a review of analytical methods, The Analyst, 144, 4139, 10.1039/C9AN00112C de Dios, 2013, Comparison of bioanalytical methods for the quantitation of PEGylated human insulin, J Immunol Methods, 396, 1, 10.1016/j.jim.2013.07.007 Guerci, 2005, Subcutaneous insulin: pharmacokinetic variability and glycemic variability, Diabetes Metab, 31, 4S, 10.1016/S1262-3636(05)88263-1 Søeborg, 2009, Absorption kinetics of insulin after subcutaneous administration, Eur J Pharm Sci, 36, 78, 10.1016/j.ejps.2008.10.018 Rasmussen, 2014, Insulin aspart pharmacokinetics: an assessment of its variability and underlying mechanisms, Eur J Pharm Sci, 62, 65, 10.1016/j.ejps.2014.05.010 Chen, 2003, Limitations to subcutaneous insulin administration in type 1 diabetes, Diabetes Obes Metab, 5, 223, 10.1046/j.1463-1326.2003.00266.x Olefsky, 1973, Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects, Diabetes, 22, 507, 10.2337/diab.22.7.507